In a phase 3 trial involving patients whose symptoms were inadequately controlled with current drugs, significantly more patients taking Dupixent (dupilumab) saw reduced itch and skin lesions ...

Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease.

Five times more adults on Dupixent achieved sustained disease remission ... and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory ...

seeking approval for Dupixent for treating bullous pemphigoid (BP), a chronic, debilitating and relapsing skin disease. With the FDA granting a priority review status to the sBLA, a decision is ...

reddening of the skin, and painful lesions. The ADEPT study met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Dupixent late-breaking positive pivotal data ... be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions ...